Financial Contrast: Tcr2 Therapeutics (TCRR) vs. The Competition
Tcr2 Therapeutics (NASDAQ: TCRR) is one of 122 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its peers? We will compare Tcr2 Therapeutics to similar companies based on the strength of its profitability, valuation, analyst recommendations, institutional ownership, earnings, risk and dividends.
This table compares Tcr2 Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Tcr2 Therapeutics Competitors||-4,670.94%||-78.86%||-35.00%|
This is a summary of recent ratings and price targets for Tcr2 Therapeutics and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Tcr2 Therapeutics Competitors||910||2952||6335||281||2.57|
Tcr2 Therapeutics currently has a consensus price target of $27.80, suggesting a potential upside of 103.81%. As a group, “Biological products, except diagnostic” companies have a potential upside of 44.47%. Given Tcr2 Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Tcr2 Therapeutics is more favorable than its peers.
Insider and Institutional Ownership
33.3% of Tcr2 Therapeutics shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 17.0% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Tcr2 Therapeutics and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Tcr2 Therapeutics||N/A||-$61.55 million||-0.14|
|Tcr2 Therapeutics Competitors||$853.15 million||$178.74 million||-0.27|
Tcr2 Therapeutics’ peers have higher revenue and earnings than Tcr2 Therapeutics. Tcr2 Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Tcr2 Therapeutics beats its peers on 7 of the 12 factors compared.
Tcr2 Therapeutics Company Profile
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Tcr2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tcr2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.